• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ElevateBio

ElevateBio

Powering the creation of cell & gene therapies at a speed the world deserves.

  • Resources
    • Resources Overview
    • Elevated Insights
    • Presentations & Publications
    • Whitepapers
  • Media
    • Media Overview
    • Press Releases
    • Featured News
  • Facilities
  • Careers
  • Contact
  • Search
  • Manufacturing & Discovery Services
    • Manufacturing & Discovery Services Overview
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
  • Media
    • Investors & Media Overview
    • Press Releases
    • Presentations & Publications
    • Elevated Insights
  • Careers
  • Facilities
  • Contact
  • Manufacturing & Discovery Services

    Manufacturing & Discovery Services Overview

    Capabilities & Services
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    Expertise
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
    • Investors

Media

News, Media, & Presentations

Stay up-to-date with the latest news from across the ElevateBio ecosystem.

Press Releases

All Press

// Jan 08, 2026

ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business

Read More about ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business

// Jan 05, 2026

ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors

Read More about ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors

// Sep 08, 2025

ElevateBio Appoints Larry Lockwood, Ph.D., as Chief Commercial Officer

Read More about ElevateBio Appoints Larry Lockwood, Ph.D., as Chief Commercial Officer

// Aug 13, 2025

ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities

Read More about ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities

// May 12, 2025

ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

Read More about ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors

// Apr 28, 2025

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

// Apr 28, 2025

ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors

Read More about ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors

// Mar 10, 2025

ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI

Read More about ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI

// Feb 24, 2025

ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease

Read More about ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease

// Jan 09, 2025

ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

// Nov 04, 2024

ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development

Read More about ElevateBio Appoints Amy Pooler Ph.D., as Senior Vice President, Research and Development

// Oct 16, 2024

ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential

Read More about ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential

// May 14, 2024

ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques

Read More about ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques

// Apr 22, 2024

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

// Jan 08, 2024

ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference  

Read More about ElevateBio to Highlight Growth of its Genetic Medicine Business Driven By Gene Editing and Manufacturing Partnerships at the 42nd Annual J.P. Morgan Healthcare Conference  

// Sep 26, 2023

Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

Read More about Kyverna Therapeutics and ElevateBio to Advance Kyverna’s Ingenui-T Cell Therapy Manufacturing

// May 24, 2023

ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

Read More about ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

// May 24, 2023

Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

Read More about Novo Nordisk and Life Edit Therapeutics Establish Multi-Target Collaboration to Discover and Develop Gene Editing Therapies for Rare and Cardiometabolic Diseases

// May 15, 2023

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production

Read More about ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production

// Apr 25, 2023

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

Read More about Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

// Mar 07, 2023

ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs

Read More about ElevateBio Appoints Heidi L. Wagner, J.D., as Global Head of Government Affairs

// Feb 22, 2023

Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Read More about Moderna and Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

// Jan 05, 2023

ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 41st Annual J.P. Morgan Healthcare Conference

// Nov 15, 2022

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

Read More about ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

// Nov 03, 2022

ElevateBio BaseCamp Unveils its LentiPeak™ Lentiviral Vector Platform

Read More about ElevateBio BaseCamp Unveils its LentiPeak™ Lentiviral Vector Platform

// Aug 25, 2022

ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation

Read More about ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation

// Aug 23, 2022

ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines

Read More about ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines

// Aug 04, 2022

ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

Read More about ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

// Jun 02, 2022

ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development

Read More about ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development

// May 04, 2022

ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read More about ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

// Jan 06, 2022

ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference

// Nov 15, 2021

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

Read More about ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

// Oct 27, 2021

ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

Read More about ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics

// Jun 29, 2021

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

Read More about Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

// Jun 10, 2021

ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

Read More about ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion

// Apr 27, 2021

ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering

Read More about ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering

// Mar 18, 2021

ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

Read More about ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

// Mar 15, 2021

ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

Read More about ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing

// Jan 19, 2021

ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp

Read More about ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp

// Jan 08, 2021

ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More about ElevateBio to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

// Jan 08, 2021

ElevateBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Read More about ElevateBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

// Jan 08, 2021

39th Annual J.P. Morgan Healthcare Conference

Read More about 39th Annual J.P. Morgan Healthcare Conference

// Dec 06, 2020

ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

Read More about ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting

// Nov 30, 2020

Piper Sandler 32nd Annual Virtual Healthcare Conference

Read More about Piper Sandler 32nd Annual Virtual Healthcare Conference

// Nov 16, 2020

ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies

Read More about ElevateBio and AgBiome Announce LifeEDIT Will Join ElevateBio’s Portfolio of Innovative Cell and Gene Therapy Companies

// Oct 28, 2020

Morgan Stanley 18th Annual Global Healthcare Conference

Read More about Morgan Stanley 18th Annual Global Healthcare Conference

// Aug 25, 2020

ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Read More about ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

// May 26, 2020

ElevateBio to Present at the Jefferies Virtual Healthcare Conference

Read More about ElevateBio to Present at the Jefferies Virtual Healthcare Conference

// Mar 30, 2020

ElevateBio Closes $170 Million Series B Financing

Read More about ElevateBio Closes $170 Million Series B Financing

// Mar 26, 2020

European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

Read More about European Medicines Agency Grants Orphan Drug Designation to AlloVir’s Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

// Mar 23, 2020

AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

Read More about AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19

// Mar 05, 2020

ElevateBio Appoints Kareem Reda as Chief Business Officer

Read More about ElevateBio Appoints Kareem Reda as Chief Business Officer

// Feb 19, 2020

AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Read More about AlloVir to Present at the SVB Leerink 9th Annual Global Healthcare Conference

// Feb 12, 2020

AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

Read More about AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy

// Dec 09, 2019

ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine

Read More about ElevateBio Appoints Melissa K. Carpenter, Ph.D., as Chief Scientific Officer of Regenerative Medicine

// Oct 01, 2019

ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research

Read More about ElevateBio Launches HighPassBio to Advance Novel Targeted T Cell Immunotherapies with Technology from Fred Hutchinson Cancer Research

// Sep 10, 2019

Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Read More about Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

// Jul 25, 2019

Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies

Read More about Massachusetts General Hospital and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene Therapies

// Jun 11, 2019

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

Read More about AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT

// May 22, 2019

ElevateBio announces that Allovir joins its portfolio of highly innovative cell and gene therapy companies

Read More about ElevateBio announces that Allovir joins its portfolio of highly innovative cell and gene therapy companies

// May 13, 2019

ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

Read More about ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies

Featured News

All Featured News

// Mar 12, 2026 | Pharma Manufacturing

ElevateBio BaseCamp Pittsburgh seen as model for US manufacturing

Read More

// Feb 27, 2026 | Pittsburgh Business Times

Viewpoint: The U.S. government is betting big on biotech: Is this Pittsburgh’s moment to lead?

Read More

// Nov 05, 2025 | Pharma Manufacturing

Well-funded startup ElevateBio looks to attain critical manufacturing mass

With $1.3 billion in funding, the company has established a cGMP manufacturing facility in Waltham, Massachusetts, with a second site under construction in Pittsburgh.

Read More

// Oct 07, 2025 | BioSpace

BioSpace Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit

The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.

Read More

// Aug 14, 2025 | BioPharm

ElevateBio BaseCamp Achieves First Multi-Modality ICMC Certification in Commercial CGT Manufacturing

ElevateBio's BaseCamp facility achieved ICMC certification for multi-modal manufacturing capabilities, marking a first in genetic medicines manufacturing.

Read More

// Jun 12, 2025 | CNBC

CNBC Disruptor 50: ElevateBio CEO Ger Brophy on AI and CRISPR for rare disease treatments

ElevateBio CEO Ger Brophy joins ‘Worldwide Exchange’ as ElevateBio ranks #43 on the Disruptor 50 list.

Read More

// Mar 11, 2025 | Drug Target Review

AWS and ElevateBio join forces to advance gene editing

ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.

Read More

// May 23, 2024 | Cell and Gene Therapy

Outsourced Pharma Capacity Update May 2024

Debaditya Bhattacharya, Ph.D. VP, Analytical Development and Miranda Williams Scientist I, Analytical Development discuss BaseCamp’s analytical capabilities and more in a recorded webcast.

Read More

// May 14, 2024 | CNBC

ElevateBio CEO on disruptive potential for gene and cell therapies

David Hallal, ElevateBio CEO, joins ‘Fast Money’ to talk making CNBC’s Disruptor 50 list, what is included in its portfolio, innovation in cell and gene therapy and more.

Read More

// May 24, 2023 | Fierce Biotech

ElevateBio takes fundraising crown with $401M series D, adds Novo Nordisk to growing army of partners

Move over, ReNAgade Therapeutics. After just one day, ElevateBio’s $401 million haul has already bumped the RNA company’s $300 million series A out of the running for the largest private biotech fundraise of 2023. 

Read More

// Feb 28, 2023 | The Long Run

A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run

This episode was recorded in person at the JP Morgan Healthcare Conference in San Francisco. Biotech history buffs will especially enjoy the first half, where he talks about what pharmaceutical sales was like and what it was like to work at Amgen in the early days.

Read More

// Oct 12, 2022 | Biotech 2050 Podcast

A New Vision for Cell and Gene Therapy, Andrew Sandford & Michael Paglia, ElevateBio BaseCamp

Andrew Sandford and Michael Paglia are the President and COO, respectively, of ElevateBio BaseCamp, a cell and gene therapy technology company powering transformative therapies. They join us from the company’s manufacturing facilities in Waltham, Massachusetts, for a discussion about the landscape of company creation in the cell and gene therapy space and how ElevateBio is helping companies bring innovation and therapeutics to clinics and patients to help treat and cure diseases.

Read More

// Aug 29, 2022 | PittWire

Pitt and ElevateBio are partnering to bring cell and gene therapy manufacturing to Pittsburgh

Elected officials, community members and University and industry leaders gathered on Hazelwood Green on Thursday to celebrate a major step forward for the regional life sciences industry: an agreement to form a 30-year strategic partnership between Pitt and biotech company ElevateBio to accelerate the development of highly innovative cell and gene therapies at Pitt BioForge.

Read More

// Jul 12, 2022 | Ori Spotlight

Mike Paglia – Chief Operating Officer, ElevateBio

Mike Paglia, COO BaseCamp, on ‘Ori Spotlight’ podcast discussing how Elevate supports the cell and gene therapy industry, the long-term benefits of digital manufacturing processes, and the importance of removing the cost barrier to CGTs.

Read More

// Jan 18, 2022 | American Builders Quarterly

Mario Miele Begins with the End in Mind

Mario Miele, VP Facilities and Engineering, article discussing the buildout of BaseCamp

Read More

Footer

ElevateBio

Investors & Media

LinkedIn Twitter

© 2026 ElevateBio. All Rights Reserved.

Privacy & Cookie Policy

  • Manufacturing & Discovery Services
  • Technologies
  • Advanced Therapies
  • Partner With Us
  • About
  • Presentations & Publications
  • Elevated Insights
  • Careers
  • Facilities
  • Contact
MENU
  • Manufacturing & Discovery Services
    • Manufacturing & Discovery Services Overview
    • Gene Editing Design & Optimization
    • Process Development
    • Analytical Development
    • cGMP Manufacturing
    • Next-Generation Sequencing
    • Quality
    • Regulatory CMC
    • Certifications & Compliance
    • Generative AI
  • Technologies
    • Technologies Overview
    • Gene Editing
    • Viral and Non-Viral Delivery
    • Messenger RNA (mRNA)
    • Induced Pluripotent Stem Cells (iPSCs)
  • Advanced Therapies
  • Partner With Us
  • About
    • About Overview
    • Our Journey
    • Our Team
    • Culture of Expedition
    • Careers
  • Media
    • Investors & Media Overview
    • Press Releases
    • Presentations & Publications
    • Elevated Insights
  • Careers
  • Facilities
  • Contact